Current Oncology (Mar 2021)

PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successfully Treated with Everolimus: A Case Report

  • Hazem I. Assi,
  • Rasha T. Kakati,
  • Juliett Berro,
  • Ibrahim Saikali,
  • Bassem Youssef,
  • Roula Hourany,
  • Ibrahim Alameh,
  • Abeer Tabbarah,
  • Jessica Khoury,
  • Houssein Darwish,
  • Saada Alame

DOI
https://doi.org/10.3390/curroncol28020121
Journal volume & issue
Vol. 28, no. 2
pp. 1274 – 1279

Abstract

Read online

Papillary tumors of the pineal region (PTPR) can be observed among adults with poor prognosis and high recurrence rates. Standards of therapy involve total surgical excision along with radiation therapy, with no promising prospects for primary adjuvant chemotherapy, as long-term treatment options have not been explored. Chromosome 10 loss is characteristic of PTPR, and PTEN gene alterations are frequently encountered in a wide range of human cancers and may be treated with mTORC1 inhibitors such as everolimus. In parallel, there are no reports of treating PTPR with everolimus alone as a monopharmacotherapy. We report the case of a patient diagnosed with PTPR (grade III) characterized by a PTEN R130Q alteration with chromosome 10 loss that was treated with everolimus pharmacotherapy alone, resulting in an asymptomatic course and tumor regression, a rare yet notable phenomenon not described in the literature so far with potential to alter the management approach to patients with PTPR.

Keywords